G-CSF and GM-CSF in Neutropenia.

Article Details

Citation Copy to clipboard

Mehta HM, Malandra M, Corey SJ

G-CSF and GM-CSF in Neutropenia.

J Immunol. 2015 Aug 15;195(4):1341-9. doi: 10.4049/jimmunol.1500861.

PubMed ID

26254266 [ View in PubMed

]

Abstract

G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias. Clinically significant neutropenia, rendering an individual immunocompromised, occurs when their number is <1500/mul. Current guidelines recommend their use when the risk for febrile neutropenia is >20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation. Because of its promotion of APC function, GM-CSF is being evaluated as an immunostimulatory adjuvant in a number of clinical trials. More than 20 million persons have benefited worldwide, and >$5 billion in sales occur annually in the United States.

DrugBank Data that Cites this Article

Drugs

Efbemalenograstim alfa

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Topotecan Pegfilgrastim	The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.
Topotecan Filgrastim	The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan.
Topotecan Lenograstim	The risk or severity of neutropenia can be increased when Lenograstim is combined with Topotecan.
Topotecan Eflapegrastim	The risk or severity of neutropenia can be increased when Eflapegrastim is combined with Topotecan.
Topotecan Efbemalenograstim alfa	The risk or severity of neutropenia can be increased when Efbemalenograstim alfa is combined with Topotecan.